Roche Holding AG (RHHBY)
| Previous Close | 38.35 |
| Open | 38.48 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 38.40 - 38.83 |
| 52 Week Range | 37.30 - 53.86 |
| Volume | |
| Avg. Volume | 1,407,375 |
| Market Cap | 252.611B |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | 17.12 |
| EPS (TTM) | 2.27 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.24 (2.98%) |
| Ex-Dividend Date | Mar 17, 2022 |
| 1y Target Est | 46.25 |
- Business Wire
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
SOUTH SAN FRANCISCO, Calif., February 07, 2023--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the global Phase III COMMODORE 2 study, evaluating the efficacy and safety of crovalimab in people with paroxysmal nocturnal hemoglobinuria (PNH) who have not been previously treated with complement inhibitors. The study met its co-primary efficacy endpoints of transfusion avoidance and control of hemolysis (the ongoing destruction of red bloo
- GlobeNewswire
Roche announces positive data from global phase III programme for crovalimab in PNH, a rare life-threatening blood condition
The COMMODORE 2 study met its co-primary efficacy endpoints, showing crovalimab achieved disease control in people with paroxysmal nocturnal haemoglobinuria (PNH) who have not been previously treated with complement inhibitorsThe results of the phase III COMMODORE 1 study in people with PNH switching from currently approved C5 inhibitors, supported the favourable benefit-risk profile of crovalimab, as seen in the pivotal COMMODORE 2 studyResults from both studies will be submitted to regulatory
- Zacks
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.
